We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

122 hedge funds and large institutions have $842M invested in Coherus Oncology in 2016 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

68.52% more ownership

Funds ownership: 0% → 68.52% (+69%)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

32% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 19

19% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 37

14% more capital invested

Capital invested by funds: $741M → $842M (+$101M)

4% more funds holding

Funds holding: 117 → 122 (+5)

92% less call options, than puts

Call options by funds: $268K | Put options by funds: $3.3M

Holders
122
Holders Change
+5
Holders Change %
+4.27%
% of All Funds
3.05%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
25
Increased
44
Reduced
37
Closed
19
Calls
$268K
Puts
$3.3M
Net Calls
-$3.03M
Net Calls Change
+$313K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$16.8M
2
UBS AM
UBS AM
Illinois
+$13.5M
3
CC
Carlson Capital
Texas
+$11.2M
4
Ameriprise
Ameriprise
Minnesota
+$7.17M
5
JCG
JHL Capital Group
Illinois
+$7M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$13.4M
2
JP Morgan Chase
JP Morgan Chase
New York
-$10.2M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.78M
4
TCIM
TIAA CREF Investment Management
New York
-$5.19M
5
Deutsche Bank
Deutsche Bank
Germany
-$2.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lord, Abbett & Co
26
Lord, Abbett & Co
New Jersey
$7.39M -$2.83M -101,180 -28%
Ameriprise
27
Ameriprise
Minnesota
$7.22M +$7.17M +256,371 New
JCG
28
JHL Capital Group
Illinois
$7.04M +$7M +250,000 New
Geode Capital Management
29
Geode Capital Management
Massachusetts
$6.72M +$628K +22,449 +10%
CCI
30
Columbus Circle Investors
$5.95M -$2.94M -104,996 -33%
Citadel Advisors
31
Citadel Advisors
Florida
$5.9M +$2.53M +90,381 +76%
BG
32
Bellevue Group
Switzerland
$4.93M -$756K -27,000 -13%
Allianz Asset Management
33
Allianz Asset Management
Germany
$4.58M +$568K +20,300 +14%
TA
34
Teachers Advisors
New York
$4.16M +$66.4K +2,374 +2%
Morgan Stanley
35
Morgan Stanley
New York
$4.11M +$2.5M +89,276 +157%
EAM
36
Eventide Asset Management
Massachusetts
$4.08M – – –
CS
37
Credit Suisse
Switzerland
$4M -$842K -30,084 -17%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$3.94M +$165K +5,905 +4%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$3.84M +$973K +34,785 +34%
VMI
40
VHCP Management II
New York
$3.65M – – –
KCM
41
Kennedy Capital Management
Missouri
$3.46M +$1.9M +67,969 +124%
Charles Schwab
42
Charles Schwab
California
$3.36M +$158K +5,631 +5%
Two Sigma Investments
43
Two Sigma Investments
New York
$3.25M +$3.23M +115,480 New
BIM
44
BlackRock Investment Management
Delaware
$3.25M -$18.1K -646 -0.6%
RPAM
45
Rhenman & Partners Asset Management
Sweden
$3.13M -$560K -20,000 -15%
Deutsche Bank
46
Deutsche Bank
Germany
$2.83M -$2.97M -106,310 -51%
EAM
47
EverPoint Asset Management
Connecticut
$2.81M +$2.8M +100,000 New
CWG
48
C WorldWide Group
Denmark
$2.67M -$1.74M -62,124 -40%
TCM
49
Tekla Capital Management
Massachusetts
$2.53M +$2.52M +90,000 New
LOAMS
50
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.11M -$700K -25,000 -25%
1
2
3 4 5

CHRS Hedge Fund Activity: Q4 2016 in Review

122 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2016, worth a combined $842M — up 14% from $741M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CHRS positions and 19 closed out — a net gain of 6 holders — while 44 added to existing stakes and 37 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $16.8M. The largest seller was Millennium Management, cutting an estimated $13.4M.

  • 122 institutional investors held Coherus Oncology (CHRS) as of Q4 2016, up from 117 in Q3 2016.
  • Funds reported $842M of Coherus Oncology stock for Q4 2016, up 14% quarter-over-quarter.
  • 25 funds opened new Coherus Oncology positions in Q4 2016 and 19 closed out, a net change of +6 holders.
  • The largest Coherus Oncology buyer in Q4 2016 was Point72 Asset Management, an estimated $16.8M added.
  • The largest Coherus Oncology seller in Q4 2016 was Millennium Management, an estimated $13.4M sold.

Based on aggregated 13F filings for Q4 2016.